Home / Executive Moves / Fluor Names Raytheon, Northrop Vet Biggs Porter CFO, SVP

Fluor Names Raytheon, Northrop Vet Biggs Porter CFO, SVP

Fluor Corp. (NYSE: FLR) has appointed Biggs C. Porter as chief financial officer and senior vice president, the company announced Wednesday.

Porter will join the company’s headquarters in Irving, Texas, on April 9 and officially begin serving in the CFO role May 4.

The company said that is when it finishes reporting its financial results for its first quarter of 2012.

In that role, Porter will lead the company’s finance, audit, investor relations, mergers and acquisitions and compliance and ethics functions.

Porter succeeds D. Michael Steuert, who will retire from Fluor after 11 years with the company at the end of May, but continue working with the company through 2012 as a consultant.

“In the post Sarbanes-Oxley world, Mike led our efforts to develop and implement world-class financial reporting systems across our global network and enhanced our risk management capabilities, ” said Chairman and CEO David Seaton.

“We appreciate all that Mike has done for Fluor during his tenure as CFO and we wish him the best in retirement.”

Porter joins Fluor from Tenet Healthcare, where he served as CFO for six years and oversaw functions including and related to finance, accounting and investor relations.

He previously held senior finance positions at Raytheon (NYSE: RTN) and Dallas-based utility firm TXU Corp. He also held a finance position at Northrop Grumman (NYSE: NOC).

Seaton assumed the chairman position on the company’s board of directors, succeeding Alan Boeckman in that role. Seaton previously succeeded Boeckman as company CEO in February 2011.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.